Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-21-030046
Filing Date
2021-07-26
Accepted
2021-07-26 21:22:29
Documents
1
Period of Report
2021-07-26

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1515
  Complete submission text file 0000899243-21-030046.txt   3027
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Issuer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address NORTHPOND VENTURES 7500 OLD GEORGETOWN ROAD BETHESDA MD 20814
Business Address
Gandhi Shaan-Chirag C (Reporting) CIK: 0001873448 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40629 | Film No.: 211115693